Cancer Capital Corp financial data

Symbol
CNCL on OTC
Industry
Blank Checks
Location
440 East 400 South, Ste 300, Salt Lake City, UT
State of incorporation
Wyoming
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.65 % -40.8%
Debt-to-equity -101 % +3.5%
Return On Equity 9.52 % -0.94%
Return On Assets -355 % -73.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.15M shares
Common Stock, Shares, Outstanding 6.15M shares 0%
Entity Public Float 0 USD
Common Stock, Value, Issued 6.15K USD 0%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 20.3K USD +15%
Operating Income (Loss) -20.3K USD -15%
Net Income (Loss) Attributable to Parent -43.6K USD -8.81%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.16K USD -68.7%
Assets, Current 5.16K USD -68.7%
Assets 5.16K USD -68.7%
Accounts Payable, Current 1.35K USD -55%
Liabilities, Current 480K USD +7.2%
Liabilities 480K USD +7.2%
Retained Earnings (Accumulated Deficit) -528K USD -8.98%
Stockholders' Equity Attributable to Parent -475K USD -10.1%
Liabilities and Equity 5.16K USD -68.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.5K USD +16.6%
Net Cash Provided by (Used in) Financing Activities 28K USD
Common Stock, Shares Authorized 20M shares 0%
Common Stock, Shares, Issued 6.15M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.5K USD +16.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.16K USD -68.7%
Deferred Tax Assets, Valuation Allowance 106K USD +8.13%
Deferred Tax Assets, Operating Loss Carryforwards 106K USD +8.13%
Additional Paid in Capital 47.1K USD 0%
Interest Expense 10.4K USD +1.67%